This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yu, Y. P. Articles by Luo, J.-H. Search for Related Content PubMed PubMed Citation Articles by Yu, Y. P. Articles by Luo, J.-H.

Myopodin-Mediated Suppression of Prostate Cancer Cell Migration Involves Interaction with Zyxin

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

Requests for reprints: Yan Ping Yu, Department of Pathology, University of Pittsburgh, Scaife S-741, 3550 Terrace Street, Pittsburgh, PA 15261. Phone: 412-383-7815; Fax: 412-648-5997; E-mail: ypyu{at}pitt.edu.

Myopodin was identified as a tumor suppressor gene that is frequently deleted in aggressive prostate cancer. Expression of myopodin protein suppresses both tumor growth and metastasis in vitro and in vivo. In the present study employing a yeast two-hybrid system, we found that zyxin, a molecule known to regulate cell motility and migration, binds with myopodin with high affinity. The binding between zyxin and myopodin seems to be direct. Screening of a series of myopodin deletion mutants and peptide competition analyses revealed that myopodin is bound by zyxin at a site located within the sequence of the 19 amino acids at the myopodin COOH terminus. Importantly, this is the same region where the tumor suppressor activity of myopodin is located. The motility and invasion suppression activity of myopodin were significantly weakened in myopodin mutants lacking this sequence. Thus, our studies suggest that zyxin may be a critical functional regulator of myopodin. (Cancer Res 2006; 66(15): 7414-9)

This article has been cited by other articles:

				C. R. Evelyn, S. M. Wade, Q. Wang, M. Wu, J. A. Iniguez-Lluhi, S. D. Merajver, and R. R. Neubig CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling Mol. Cancer Ther., August 1, 2007; 6(8): 2249 - 2260. [Abstract] [Full Text] [PDF]

				B. Ren, Y. P. Yu, G. C. Tseng, C. Wu, K. Chen, U. N. Rao, J. Nelson, G. K. Michalopoulos, and J.-H. Luo Analysis of Integrin {alpha}7 Mutations in Prostate Cancer, Liver Cancer, Glioblastoma Multiforme, and Leiomyosarcoma J Natl Cancer Inst, June 6, 2007; 99(11): 868 - 880. [Abstract] [Full Text] [PDF]